Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free
Eric  Venker net worth and biography

Eric Venker Biography and Net Worth

Dr. Eric Venker serves as Chief Operating Officer of Roivant Sciences. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.

What is Eric Venker's net worth?

The estimated net worth of Eric Venker is at least $6.15 million as of February 9th, 2024. Dr. Venker owns 532,207 shares of Roivant Sciences stock worth more than $6,152,313 as of February 23rd. This net worth estimate does not reflect any other assets that Dr. Venker may own. Additionally, Dr. Venker receives a salary of $1,280,000.00 as COO at Roivant Sciences. Learn More about Eric Venker's net worth.

How old is Eric Venker?

Dr. Venker is currently 37 years old. There are 5 older executives and no younger executives at Roivant Sciences. The oldest executive at Roivant Sciences is Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management, who is 56 years old. Learn More on Eric Venker's age.

What is Eric Venker's salary?

As the COO of Roivant Sciences Ltd., Dr. Venker earns $1,280,000.00 per year. There are 2 executives that earn more than Dr. Venker. The highest earning executive at Roivant Sciences is Mr. Matthew Gline, CEO & Director, who commands a salary of $1,770,000.00 per year. Learn More on Eric Venker's salary.

How do I contact Eric Venker?

The corporate mailing address for Dr. Venker and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Eric Venker's contact information.

Has Eric Venker been buying or selling shares of Roivant Sciences?

Within the last three months, Eric Venker has sold $1,058,694.00 in Roivant Sciences stock. Most recently, Eric Venker sold 96,950 shares of the business's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a transaction totalling $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares of the company's stock, valued at $5,811,700.44. Learn More on Eric Venker's trading history.

Who are Roivant Sciences' active insiders?

Roivant Sciences' insider roster includes Rakhi Kumar (CAO), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.

Are insiders buying or selling shares of Roivant Sciences?

In the last year, Roivant Sciences insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. In the last year, insiders at the sold shares 36 times. They sold a total of 47,655,718 shares worth more than $493,440,409.39. The most recent insider tranaction occured on February, 9th when COO Eric Venker sold 96,950 shares worth more than $1,058,694.00. Insiders at Roivant Sciences own 4.6% of the company. Learn More about insider trades at Roivant Sciences.

Information on this page was last updated on 2/9/2024.

Eric Venker Insider Trading History at Roivant Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2024Sell96,950$10.92$1,058,694.00532,207View SEC Filing Icon  
10/5/2023Sell153,027$10.11$1,547,102.97595,397View SEC Filing Icon  
10/2/2023Sell440,752$10.80$4,760,121.60595,397View SEC Filing Icon  
9/27/2023Sell500,000$13.02$6,510,000.00595,397View SEC Filing Icon  
9/8/2023Sell106,430$12.19$1,297,381.70611,813View SEC Filing Icon  
9/6/2023Sell5,926$11.85$70,223.10611,813View SEC Filing Icon  
9/1/2023Sell14,763$11.90$175,679.70611,813View SEC Filing Icon  
8/14/2023Sell59,811$11.89$711,152.79627,918View SEC Filing Icon  
8/2/2023Sell16,397$11.86$194,468.42627,918View SEC Filing Icon  
7/31/2023Sell117,372$11.91$1,397,900.52627,918View SEC Filing Icon  
7/26/2023Sell73,568$10.91$802,626.88627,918View SEC Filing Icon  
7/24/2023Sell33,081$10.93$361,575.33644,215View SEC Filing Icon  
7/21/2023Sell181,998$11.13$2,025,637.74644,215View SEC Filing Icon  
6/9/2023Sell299,384$9.91$2,966,895.44660,097View SEC Filing Icon  
6/7/2023Sell201$9.85$1,979.85660,097View SEC Filing Icon  
5/23/2023Sell415$9.85$4,087.75675,768View SEC Filing Icon  
5/8/2023Sell61,206$8.93$546,569.58675,768View SEC Filing Icon  
5/4/2023Sell88,838$8.30$737,355.40675,768View SEC Filing Icon  
5/2/2023Sell109,074$8.29$904,223.46675,768View SEC Filing Icon  
4/27/2023Sell73,514$8.51$625,604.14675,768View SEC Filing Icon  
1/5/2023Sell24,037$8.02$192,776.74729,429View SEC Filing Icon  
1/3/2023Sell95,484$7.32$698,942.88753,466View SEC Filing Icon  
12/8/2022Sell11,729$7.00$82,103.001,022,118View SEC Filing Icon  
10/25/2022Sell15,922$4.40$70,056.801,049,850View SEC Filing Icon  
9/23/2022Sell17,392$3.07$53,393.441,065,772View SEC Filing Icon  
8/24/2022Sell16,530$3.71$61,326.301,083,164View SEC Filing Icon  
7/25/2022Sell16,896$4.33$73,159.681,099,694View SEC Filing Icon  
6/23/2022Sell16,402$4.34$71,184.681,116,590View SEC Filing Icon  
5/20/2022Sell136,421$3.70$504,757.701,132,992View SEC Filing Icon  
4/25/2022Sell5,107$3.84$19,610.881,269,413View SEC Filing Icon  
3/30/2022Sell19,336$4.84$93,586.24View SEC Filing Icon  
3/25/2022Sell80,045$5.06$405,027.70View SEC Filing Icon  
See Full Table

Eric Venker Buying and Selling Activity at Roivant Sciences

This chart shows Eric Venker's buying and selling at Roivant Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roivant Sciences Company Overview

Roivant Sciences logo
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $11.60
Low: $11.28
High: $11.68

50 Day Range

MA: $10.86
Low: $9.89
High: $11.60

2 Week Range

Now: $11.60
Low: $6.59
High: $13.24

Volume

3,398,404 shs

Average Volume

5,407,625 shs

Market Capitalization

$9.33 billion

P/E Ratio

2.23

Dividend Yield

N/A

Beta

1.34
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Here's what you need to do now to profit.